Investor deploying $1.2M into TNDM, betting on PayGo's 2027 projections and market opportunity as competitors like Insulet and Mint struggle with product execution in the insulin pump space. Key risks include competition from newer tubeless pump alternatives and execution delays on PayGo launch.

Investor betting $886k on TNDM based on anticipated FDA approval of tubeless pump before year-end, strong Q2 earnings with new pay-go system, and analyst price target of $55. Key risks include unproven pump market adoption, historical September weakness, and regulatory approval uncertainty.

Author believes Tandem Diabetes is undervalued and positioned for significant growth, either through a 10x stock appreciation or acquisition at a premium price within the next few years. Key risks include competitive threats from larger medical device companies, regulatory challenges, reliance on key products, and the possibility of acquisition at a price lower than the 10x target.